Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Studied

Randomized, double-blind phase 3 trial compared weekly retatrutide with placebo for 40 weeks. The primary outcome was HbA1c, a blood-sugar marker; weight change was secondary.

Who / model

537 adults with type 2 diabetes inadequately controlled by diet and exercise alone were randomized.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

HbA1c fell 1·69–1·94 percentage points across retatrutide groups versus 0·81 with placebo. Weight fell 11·5–15·3% versus 2·6%. Gastrointestinal events were generally mild or moderate; adverse-event discontinuations were 2–5% versus 0%. No severe low blood sugar occurred. Two deaths were judged unrelated to treatment.

Limits

No author-stated limitations were available in the abstract. The comparison covered 40 weeks against placebo, not an active drug.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary